Elucidation of cardiac muscle fibrosis mechanism by renin-angiotensin system through chymase
肾素-血管紧张素系统通过食糜酶阐明心肌纤维化机制
基本信息
- 批准号:16580268
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2004
- 资助国家:日本
- 起止时间:2004 至 2005
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In chronic heart failure, renin- angiotensin (RAS) system is enhanced. Angiotensin converting enzyme and chymase are present in RAS system, and these enzymes may affect pathophysiologically in cardiac failure. In this study, response to tissue RAS of ACE inhibitor (enalapril) and Ang II type receptor blocker (ARB : Candesartan) were examined. Hamsters with an aortic coarctation were given ACE inhibitor and ARB. Cardiac muscle hyperplasia depression was observed in ACE inhibitor and ARB administrated group by echocardiography, and the decrease that was significant in heart / body weight ratio was observed. The left ventricle ACE and the chymase activity were not inhibited by ACE inhibitor and ARB. However, decreased systolic blood pressure and decrease of left ventricle Ang II were observed by ACE inhibitor and ARB, and this tendency was more massive in a combined medication. These results suggested increasing afterload and tissue Ang II contribute cardiac hypertrophy in pressure overload.
慢性心力衰竭时,肾素-血管紧张素(RAS)系统增强. RAS系统中存在血管紧张素转换酶和糜酶,这些酶在心力衰竭中可能发挥病理生理作用。在这项研究中,ACE抑制剂(依那普利)和血管紧张素II型受体阻滞剂(ARB:坎地沙坦)对组织RAS的反应进行了检查。对患有主动脉缩窄的仓鼠给予ACE抑制剂和ARB。超声心动图显示ACE抑制剂和ARB组心肌增生明显抑制,心/体重比明显降低。ACE抑制剂和ARB对左心室ACE和糜酶活性无明显抑制作用。而ACE抑制剂和ARB均能降低收缩压和左心室Ang Ⅱ水平,且联合用药时降低幅度更大。提示压力超负荷时,后负荷增加和组织中Ang Ⅱ的增加是导致心肌肥厚的重要因素.
项目成果
期刊论文数量(28)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats
- DOI:10.1292/jvms.65.1057
- 发表时间:2003-10-01
- 期刊:
- 影响因子:1.2
- 作者:Uechi, M;Matsuoka, M;Ishikawa, Y
- 通讯作者:Ishikawa, Y
Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice
- DOI:10.1016/j.phrs.2006.01.001
- 发表时间:2006-04-01
- 期刊:
- 影响因子:9.3
- 作者:Kizaki, K;Ito, R;Hara, Y
- 通讯作者:Hara, Y
A Comparison of Angiotensin Converting Enzyme and Chymase Activity in the Heart of Cats,Dogs and Hamsters.
猫、狗和仓鼠心脏中血管紧张素转换酶和食糜酶活性的比较。
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:Aramaki Y;Uechi M;Takase K
- 通讯作者:Takase K
A Comparison of Angiotensin Converting Enzyme and Chymase Activity in the Heart of Cats, Dogs and Hamsters.
猫、狗和仓鼠心脏中血管紧张素转化酶和食糜酶活性的比较。
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:Aramaki Y;Uechi M;Takase K.
- 通讯作者:Takase K.
Cardiovascular Effects of Phosphodiesterase III inhibitor in Presence of Carvedilol in Dogs.
卡维地洛存在下磷酸二酯酶 III 抑制剂对狗心血管的影响。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Uechi M;Hori Y;Fujimoto K;Saitou Y;Maekawa S
- 通讯作者:Maekawa S
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
UECHI Masami其他文献
UECHI Masami的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('UECHI Masami', 18)}}的其他基金
Evaluation of Implantation of Autologous In Vivo Tissue-Engineered Valved after Valve Transplantation
瓣膜移植后自体体内组织工程瓣膜的植入评价
- 批准号:
22580369 - 财政年份:2010
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AUTONOMIC REGURATION AND CARDIAC FUNCTION IN MITRAL REGURGITATION.
二尖瓣反流中的自主调节和心脏功能。
- 批准号:
11836011 - 财政年份:1999
- 资助金额:
$ 2.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
开发工程化 Cas 效应器,用于眼内体内细胞靶向递送,以治疗常染色体显性 BEST 疾病
- 批准号:
10668167 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine
HCV 包膜纳米颗粒疫苗的精密糖工程
- 批准号:
10759994 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control
控制马尔堡病毒病暴发的预防性免疫治疗
- 批准号:
10697211 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Development of antibodies to specific cell surface markers to assess macrophage polarization during Adenovirus 14 and 14p1 infection in the Syrian hamster
开发针对特定细胞表面标记物的抗体,以评估叙利亚仓鼠腺病毒 14 和 14p1 感染期间的巨噬细胞极化
- 批准号:
10725702 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy
膜修复作为治疗贝克尔肌营养不良症的治疗干预措施
- 批准号:
10761285 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Advancing Development of Novel Immunotherapy for Chemotherapy-induced Peripheral Neuropathy (CIPN)
推进化疗引起的周围神经病变 (CIPN) 的新型免疫疗法的发展
- 批准号:
10588384 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
用于治疗马尔堡病毒病的单克隆抗体混合物
- 批准号:
10761372 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
ISPRI-HCP 的验证和改进:工艺相关蛋白质杂质免疫原性风险评估的创新平台
- 批准号:
10603538 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:














{{item.name}}会员




